Goldberg
Law PC (www.Goldberglawpc.com)
announces that a class action lawsuit has been filed against CorMedix,
Inc. (“CorMedix” or the “Company”) (NYSE: CRMD),
for alleged violations of the federal securities laws. Investors who
purchased or otherwise acquired shares between March 12, 2011 and July
29, 2015, inclusive (the “Class Period”), have until September 4, 2015
to serve as lead plaintiff in the class action.
If you are a shareholder who suffered a loss during the Class Period, we
advise you to contact Michael
Goldberg or Brian Schall,
of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey,
CA 90292, at 800-977-7401, to discuss your rights without cost to you.
You can also reach us through the firm’s website at http://www.Goldberglawpc.com,
or by email at info@goldberglawpc.com.
The class in this case has not yet been certified, and until
certification occurs, you are not represented by an attorney. If you
choose to take no action, you can remain an absent class member.
CorMedix is a biopharmaceutical company that in-licenses, develops and
markets products for the treatment of cardiac, renal, and infectious
diseases. According to the complaint, on June 29, 2015, SeekingAlpha.com
published a report on CorMedix alleging, among other things, that: (1)
CorMedix’s main product is based on a 1970s-era catheter product
acquired for less than $1 million in a bankruptcy sale, apparently after
at least two failed sales processes; (2) CorMedix's market size claims
are greatly exaggerated; and (3) CorMedix is touting misleading
clinical-data, as in-depth industry research shows its
Neutrolin/Taurolidine product is a failure and “40% benefit!” versus
industry standards is inaccurate. On June 29, 2015, shares of CorMedix
fell over 16% as a result of the news.
If you have any questions concerning your legal rights in this case,
please immediately contact Goldberg Law PC at 800-977-7401, or visit our
website at http://www.Goldberglawpc.com,
or email us at info@goldberglawpc.com.
Goldberg Law PC represents shareholders around the world and specializes
in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150818006666/en/
Copyright Business Wire 2015